Mobile Wearable Devices Show Some Sleep Disturbances During Multiple Myeloma Treatment
Younger patients had a significant decrease in sleep time on days they received dexamethasone.
Multiple Myeloma
Underdosing in Patients With Cancer and Obesity: A Thing of the Past?
New guidelines recommend using the full approved doses of immunotherapy and targeted therapies for patients with cancer and obesity.
Iberdomide-Based Regimens Show Promise in Relapsed/Refractory Multiple Myeloma
The median duration of response was 35.7 weeks with iberdomide, bortezomib, and dexamethasone compared with not reached in patients who received iberdomide, daratumumab, and dexamethasone or iberdomide, bortezomib, and carfilzomib
Long-Term Follow-Up Data Support Adding Daratumumab to Lenalidomide/Dexamethasone in Transplant-Ineligible MM
The median progression-free survival was not reached in the D-Rd group compared with 34.4 months in the Rd group.
Continued Benefit Observed With Isatuximab Plus Pomalidomide and Dexamethasone in Multiple Myeloma
Adding isatuximab to pomalidomide and dexamethasone improved progression-free survival (PFS) and PFS2.
BCVA Changes and Ocular Symptoms May Aid Belamaf Dosing in Relapsed/Refractory Multiple Myeloma
Researchers sought to determine whether BCVA and ocular symptoms could help determine dosing for belantamab mafodotin in patients with r/r multiple myeloma.
MGTA-145 Plus Plerixafor Effective for Same-Day Hematopoietic Stem Cell Mobilization
Researchers sought to determine whether the combination of MGTA-145 and plerixafor would be effective for HSC mobilization for autologous transplant in patients with multiple myeloma.
Idecabtagene Vicleucel Shows Durable Response in Relapsed/Refractory Multiple Myeloma
Researchers sought to determine whether idecabtagene vicleucel would have durable responses in heavily pretreated patients with relapsed or refractory multiple myeloma.
Oral Selinexor, Pomalidomide, and Dexamethasone Combination Is Safe in Pretreated Patients With Multiple Myeloma
Researchers sought to determine whether selinexor could be safely combined with pomalidomide and dexamethasone in heavily pretreated patients with multiple myeloma.
Age and Race May Determine Whether Cancer Patients Access Their Electronic Health Records
Black cancer patients were 44% less likely than White patients to enroll in a portal that provides access to electronic health records.
- Loading...
Loading...
Next post in General Oncology
Loading... 
Loading...